

Supporting Information

Hybrid Spherical Nucleotide Nanoparticles Can Enhance Synergistic Anti-Tumor Effect of CTLA-4 and PD-1 Blockades

Jing Zhang^{1#}, Dan Liu^{1#}, Jiale Liu¹, Yanfeng Han², Haiyan Xu³, Xigang Leng¹, Deling Kong^{1,4}, Lanxia Liu^{1*}

1. The Tianjin Key Laboratory of Biomaterials, Institute of Biomedical Engineering, Peking Union Medical College & Chinese Academy of Medical Sciences, Tianjin 300192, China
2. The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst NSW2010, Australia
3. Institute of Basic Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing 100005, China
4. College of Life Science, Nankai University, Tianjin300071, China

Jing Zhang and Dan Liu contributed equally to this work.

*Corresponding author

Lanxia Liu, Ph.D.

Professor

Institute of Biomedical Engineering, Peking Union Medical College & Chinese Academy of Medical Sciences.

Phone & Fax: +86 (22) 87891191

E-mail:

liulanxiabme@163.com

Supplementary Figures




Figure S1. Gel retardation assay show the ability of cationic PLGA-S-S-PEG/DOTAP nanoparticles (PPD NPs) to absorb nucleotides at different N/P ratio.




Figure S2. Size changes of PLGA-S-S-PEG/DOTAP nanoparticles incubated with DTT show that these nanoparticles possessed redox responsive property.




Figure S3. Uptake of siRNA in CD3⁺CD4⁺ T cells were evaluated after splenic lymphocytes were treated with FAM-labeled free siRNA, pSNPs, pSNPs & cSNPs or hSNPs for 4 hours, respectively.




Figure S4. Uptake of siRNA by CD3⁺CD8⁺ T cells after splenic lymphocytes were treated with FAM-labeled free siRNA, pSNPs, pSNPs & cSNPs or hSNPs for 4 hours, respectively.




Figure S5. Representative FACS plots of percentage of CD3⁺CD8⁺ T cells in the spleen after mice were treated 3 times with PBS, pSNPs, cSNPs, pSNPs & cSNPs and hSNPs every 5 days, respectively.




Figure S6. Representative FACS plots of percentage of CD3⁺CD4⁺ T cells in the spleen after mice were treated 3 times with PBS, pSNPs, cSNPs, pSNPs & cSNPs and hSNPs every 5 days, respectively.




Figure S7. The ratio of CD8 TIL to CD4 TIL was calculated to analyze the immune type in the local tumor tissue after mice were treated 3 times with PBS, pSNPs, cSNPs, pSNPs & cSNPs and hSNPs, respectively.